Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition.
The present investigation aimed at evaluating the role of fatty acid synthesis inhibition in enhancing transcutaneous delivery of levodopa (LD). Rat epidermis was treated with ethanol and various doses of cerulenin (an inhibitor of fatty acid synthase enzyme system) for reducing the normal level of fatty acids. Calcium chloride (0.1 mM) and/or verapamil (1 microM) were coapplied to cerulenin treated skin in order to modulate duration of epidermal perturbation. These treated skin portions were used for estimation of altered triglyceride content (an indicator of fatty acid synthesis), differential scanning calorimetry (DSC) analysis, and in vitro permeation of LD. Plasma concentration of LD was monitored in rats following topical application of various transdermal formulations. Application of cerulenin (0.1 or 0.15 mM/7 cm(2)) to viable rat skin inhibited approximately 60% triglyceride synthesis with respect to control at 2 h. Coapplication of calcium chloride (0.1 mM) significantly increased this inhibition, whereas verapamil application reduced this effect. The decrease in triglyceride content reduced the enthalpy of the lipid endothermic transition. The in vitro permeation of LD was enhanced 3-fold across skin excised after treatment with cerulenin. LD did not permeate across normal skin. The effective plasma concentration (C(eff)) of LD was achieved within 3 h and maintained till 10 h by a single topical application of a carbidopa-levodopa combination (1:4) to ethanol-perturbed cerulenin-treated skin. Coapplication of calcium chloride reduced the time lag to achieve C(eff) to 2 h and maintained it till 24 h. A single transdermal LD (64 mg) patch formulated with calcium chloride (0.1 mM) and cerulenin (0.1 mM) dissolved in a propylene glycol:ethanol (7:3) mixture seems to offer a noninvasive approach for transcutaneous delivery of levodopa.
Babita
Kumar
K
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147 002, Punjab, India.
Tiwary
Ashok K
AK
D000279:Administration, Cutaneous; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002152:Calorimetry, Differential Scanning; D002569:Cerulenin / Q000494:pharmacology; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000494:pharmacology; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors* / Q000187:drug effects; D005227:Fatty Acids / Q000096:biosynthesis*; D005260:Female; D007980:Levodopa / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D010539:Permeability / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012997:Solvents / Q000494:pharmacology; D014280:Triglycerides / Q000032:analysis; D014700:Verapamil / Q000494:pharmacology
D015259:Dopamine Agents; D005227:Fatty Acids; D012997:Solvents; D014280:Triglycerides; D002569:Cerulenin; D000431:Ethanol; D007980:Levodopa; D014700:Verapamil; D064429:Fatty Acid Synthases; D002118:Calcium